{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T04:05:10Z","timestamp":1792641910527,"version":"4.5.0"},"reference-count":98,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,26]],"date-time":"2023-07-26T00:00:00Z","timestamp":1690329600000},"content-version":"am","delay-in-days":328,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Nuclear Medicine"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1053\/j.semnuclmed.2022.05.001","type":"journal-article","created":{"date-parts":[[2022,5,27]],"date-time":"2022-05-27T09:02:23Z","timestamp":1653642143000},"page":"508-519","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":60,"title":["FDG-PET\/CT for Primary Staging and Detection of Recurrence of Breast Cancer"],"prefix":"10.1053","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9541-9175","authenticated-orcid":false,"given":"David","family":"Groheux","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.semnuclmed.2022.05.001_bib0001","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.bulcan.2019.01.002","article-title":"[Update of the recommendations of good clinical practice for the use of PET in oncology]","volume":"106","author":"Sala\u00fcn","year":"2019","journal-title":"Bull Cancer"},{"key":"10.1053\/j.semnuclmed.2022.05.001_bib0002","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/s00259-019-04553-8","article-title":"Good clinical practice recommendations for the use of PET\/CT in oncology","volume":"47","author":"Sala\u00fcn","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2022.05.001_bib0003","first-page":"1","article-title":"Breast cancer: Initial workup and staging with FDG-PET\/CT","author":"Groheux","year":"2021","journal-title":"Clin Transl Imaging"},{"key":"10.1053\/j.semnuclmed.2022.05.001_bib0004","doi-asserted-by":"crossref","first-page":"5038","DOI":"10.1002\/cncr.24534","article-title":"18F-fluorodeoxyglucose positron emission tomography\/computed tomography (FDG-PET\/CT) imaging in the staging and prognosis of inflammatory breast cancer","volume":"115","author":"Alberini","year":"2009","journal-title":"Cancer"},{"key":"10.1053\/j.semnuclmed.2022.05.001_bib0005","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s10549-007-9671-z","article-title":"Inflammatory breast cancer: PET\/CT, MRI, mammography, and sonography findings","volume":"109","author":"Yang","year":"2008","journal-title":"Breast Cancer Res Treat"},{"key":"10.1053\/j.semnuclmed.2022.05.001_bib0006","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1200\/JCO.2004.07.058","article-title":"18F-2-fluoro-2-deoxy-d-glucose positron emission tomography in staging of locally advanced breast cancer","volume":"22","author":"van der Hoeven","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2022.05.001_bib0007","doi-asserted-by":"crossref","first-page":"231","DOI":"10.2967\/jnumed.108.056010","article-title":"Retrospective study of 18F-FDG-PET\/CT in the diagnosis of inflammatory breast cancer: preliminary data","volume":"50","author":"Carkaci","year":"2009","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.05.001_bib0008","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1016\/j.ijrobp.2011.10.040","article-title":"Pretreatment staging positron emission tomography\/computed tomography in patients with inflammatory breast cancer influences radiation treatment field designs","volume":"8:","author":"Walker","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1053\/j.semnuclmed.2022.05.001_bib0009","doi-asserted-by":"crossref","first-page":"5","DOI":"10.2967\/jnumed.112.106864","article-title":"18F-FDG-PET\/CT in staging patients with locally advanced or inflammatory breast cancer: Comparison to conventional staging","volume":"54","author":"Groheux","year":"2013","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.05.001_bib0010","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s10549-020-05631-4","article-title":"Discrepancy between FDG-PET\/CT and contrast-enhanced CT in the staging of patients with inflammatory breast cancer: Implications for treatment planning","volume":"181","author":"Jacene","year":"2020","journal-title":"Breast Cancer Res Treat"},{"key":"10.1053\/j.semnuclmed.2022.05.001_bib0011","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.ijrobp.2008.02.056","article-title":"Effect of (18)F-FDG-PET\/CT imaging in patients with clinical stage II and III breast cancer","volume":"71","author":"Groheux","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1053\/j.semnuclmed.2022.05.001_bib0012","doi-asserted-by":"crossref","first-page":"4746","DOI":"10.1200\/JCO.2008.17.1496","article-title":"Preoperative staging of large primary breast cancer with [18F]fluorodeoxyglucose positron emission tomography\/computed tomography compared with conventional imaging procedures","volume":"26","author":"Fuster","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2022.05.001_bib0013","doi-asserted-by":"crossref","first-page":"3205","DOI":"10.1016\/j.ejca.2010.07.034","article-title":"Detection of extra-axillary lymph node involvement with FDG-PET\/CT in patients with stage II-III breast cancer","volume":"46","author":"Aukema","year":"2010","journal-title":"Eur J Cancer"},{"key":"10.1053\/j.semnuclmed.2022.05.001_bib0014","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1111\/j.1524-4741.2010.00987.x","article-title":"Additional value of PET-CT in staging of clinical stage IIB and III breast cancer","volume":"16","author":"Segaert","year":"2010","journal-title":"Breast J"},{"key":"10.1053\/j.semnuclmed.2022.05.001_bib0015","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s10549-011-1767-9","article-title":"18F-FDG-PET\/CT as a staging procedure in primary stage II and III breast cancer: comparison with conventional imaging techniques","volume":"131","author":"Koolen","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"10.1053\/j.semnuclmed.2022.05.001_bib0016","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1093\/jnci\/djs451","article-title":"Prognostic impact of 18FDG-PET-CT findings in clinical stage III and IIB breast cancer","volume":"104","author":"Groheux","year":"2012","journal-title":"J Natl Cancer Inst"},{"key":"10.1053\/j.semnuclmed.2022.05.001_bib0017","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1007\/s00259-013-2595-4","article-title":"18F-FDG-PET\/CT provides powerful prognostic stratification in the primary staging of large breast cancer when compared with conventional explorations","volume":"41","author":"Cochet","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2022.05.001_bib0018","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.2967\/jnumed.114.143297","article-title":"Retrospective analysis of 18F-FDG-PET\/CT for staging asymptomatic breast cancer patients younger than 40 years","volume":"55","author":"Riedl","year":"2014","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.05.001_bib0019","doi-asserted-by":"crossref","DOI":"10.1007\/s00330-015-3630-6","article-title":"(18)\u2009F-FDG-PET\/CT for initial staging in breast cancer patients - Is there a relevant impact on treatment planning compared to conventional staging modalities?","author":"Krammer","year":"2015","journal-title":"Eur Radiol"},{"key":"10.1053\/j.semnuclmed.2022.05.001_bib0020","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.2967\/jnumed.111.093864","article-title":"The yield of 18F-FDG-PET\/CT in patients with clinical stage IIA, IIB, or IIIA breast cancer: A prospective study","volume":"52","author":"Groheux","year":"2011","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.05.001_bib0021","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s10549-014-2924-8","article-title":"Additional value of F-18 FDG-PET\/CT for initial staging in breast cancer with clinically negative axillary nodes","volume":"145","author":"Jeong","year":"2014","journal-title":"Breast Cancer Res Treat"},{"key":"10.1053\/j.semnuclmed.2022.05.001_bib0022","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1097\/MNM.0000000000000671","article-title":"Diagnostic and prognostic impact of fluorine-18-fluorodeoxyglucose PET\/CT in preoperative and postoperative setting of breast cancer patients","volume":"38","author":"Evangelista","year":"2017","journal-title":"Nucl Med Commun"},{"key":"10.1053\/j.semnuclmed.2022.05.001_bib0023","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s11307-005-0013-4","article-title":"Performance of 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography and integrated PET\/CT in restaged breast cancer patients","volume":"7","author":"Fueger","year":"2005","journal-title":"Mol Imaging Biol"},{"key":"10.1053\/j.semnuclmed.2022.05.001_bib0024","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1002\/cncr.22292","article-title":"The role of FDG-PET\/CT in suspected recurrence of breast cancer","volume":"107","author":"Radan","year":"2006","journal-title":"Cancer"},{"key":"10.1053\/j.semnuclmed.2022.05.001_bib0025","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1097\/01.rct.0000284394.83696.42","article-title":"F-18-fluoro-2-deoxyglucose positron emission tomography\/computed tomography in the follow-up of breast cancer with elevated levels of tumor markers","volume":"31","author":"Haug","year":"2007","journal-title":"J Comput Assist Tomogr"},{"key":"10.1053\/j.semnuclmed.2022.05.001_bib0026","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1259\/bjr\/17395663","article-title":"FDG-PET\/CT in restaging of patients with recurrent breast cancer: Possible impact on staging and therapy","volume":"80","author":"Veit-Haibach","year":"2007","journal-title":"Br J Radiol"},{"key":"10.1053\/j.semnuclmed.2022.05.001_bib0027","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ejrad.2007.10.021","article-title":"Comprehensive imaging of tumor recurrence in breast cancer patients using whole-body MRI at 1.5 and 3 T compared to FDG-PET-CT","volume":"65","author":"Schmidt","year":"2008","journal-title":"Eur J Radiol"},{"key":"10.1053\/j.semnuclmed.2022.05.001_bib0028","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.ejrad.2008.10.031","article-title":"Integrated contrast-enhanced diagnostic whole-body PET\/CT as a first-line restaging modality in patients with suspected metastatic recurrence of breast cancer","volume":"73","author":"Dirisamer","year":"2010","journal-title":"Eur J Radiol"},{"key":"10.1053\/j.semnuclmed.2022.05.001_bib0029","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ejso.2009.11.009","article-title":"The role of FDG-PET\/CT in patients with locoregional breast cancer recurrence: A comparison to conventional imaging techniques","volume":"36","author":"Aukema","year":"2010","journal-title":"Eur J Surg Oncol"},{"key":"10.1053\/j.semnuclmed.2022.05.001_bib0030","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.ejrad.2010.04.029","article-title":"18F-FDG-PET\/CT in patients with breast cancer and rising Ca 15-3 with negative conventional imaging: A multicentre study","volume":"80","author":"Grassetto","year":"2011","journal-title":"Eur J Radiol"},{"issue":"2","key":"10.1053\/j.semnuclmed.2022.05.001_bib0031","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s00259-010-1626-7","article-title":"Tumour markers and FDG-PET\/CT for prediction of disease relapse in patients with breast cancer","volume":"38","author":"Evangelista","year":"2011","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2022.05.001_bib0032","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1002\/cncr.25727","article-title":"Breast cancer recurrence diagnosis suspected on tumor marker rising: Value of whole-body 18FDG-PET\/CT imaging and impact on patient management","volume":"117","author":"Champion","year":"2011","journal-title":"Cancer"},{"key":"10.1053\/j.semnuclmed.2022.05.001_bib0033","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1097\/MNM.0b013e3283516716","article-title":"Clinical utility of F-18 FDG-PET\/CT in recurrent breast carcinoma","volume":"33","author":"Manohar","year":"2012","journal-title":"Nucl Med Commun"},{"key":"10.1053\/j.semnuclmed.2022.05.001_bib0034","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0115127","article-title":"Role of 2-[18F] fluoro-2-deoxy-D-glucose-positron emission tomography\/computed tomography in the post-therapy surveillance of breast cancer","volume":"9","author":"Chang","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1053\/j.semnuclmed.2022.05.001_bib0035","doi-asserted-by":"crossref","unstructured":"Cochet A, David S, Moodie K, et al: The utility of 18 F-FDG-PET\/CT for suspected recurrent breast cancer: Impact and prognostic stratification. Cancer Imaging. 2014;14:13. doi:10.1186\/1470-7330-14-13","DOI":"10.1186\/1470-7330-14-13"},{"key":"10.1053\/j.semnuclmed.2022.05.001_bib0036","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1038\/bjc.2015.8","article-title":"Early detection of metastatic disease in asymptomatic breast cancer patients with whole-body imaging and defined tumour marker increase","volume":"112","author":"Di Gioia","year":"2015","journal-title":"Br J Cancer"},{"key":"10.1053\/j.semnuclmed.2022.05.001_bib0037","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1007\/s00259-002-0880-8","article-title":"FDG uptake in breast cancer: correlation with biological and clinical prognostic parameters","volume":"29","author":"Buck","year":"2002","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2022.05.001_bib0038","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1200\/JCO.2002.20.2.379","article-title":"Biologic correlates of (18)fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography","volume":"20","author":"Bos","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2022.05.001_bib0039","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1097\/MNM.0000000000001376","article-title":"Correlation between semiquantitative and volumetric 18F-FDG-PET\/omputed tomography parameters and Ki-67 expression in breast cancer","volume":"42","author":"Mohamadien","year":"2021","journal-title":"Nucl Med Commun"},{"key":"10.1053\/j.semnuclmed.2022.05.001_bib0040","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1007\/s00259-010-1640-9","article-title":"Correlation of high (18)F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer","volume":"38","author":"Groheux","year":"2011","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2022.05.001_bib0041","doi-asserted-by":"crossref","unstructured":"Iqbal R, Mammatas LH, Aras T, et al: Diagnostic performance of [18F]FDG-PET in staging grade 1-2, estrogen receptor positive breast cancer. Diagnostics (Basel). 2021;11:1954. https:\/\/doi.org\/10.3390\/diagnostics11111954","DOI":"10.3390\/diagnostics11111954"},{"key":"10.1053\/j.semnuclmed.2022.05.001_bib0042","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s00259-014-2941-1","article-title":"Prognostic impact of 18F-FDG-PET\/CT staging and of pathological response to neoadjuvant chemotherapy in triple-negative breast cancer","volume":"42","author":"Groheux","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2022.05.001_bib0043","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1007\/s00259-013-2616-3","article-title":"Prognostic relevance at 5 years of the early monitoring of neoadjuvant chemotherapy using (18)F-FDG-PET in luminal HER2-negative breast cancer","volume":"41","author":"Humbert","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2022.05.001_bib0044","doi-asserted-by":"crossref","first-page":"95","DOI":"10.18632\/oncotarget.27851","article-title":"Harmonized pretreatment quantitative volume-based FDG-PET\/CT parameters for prognosis of stage I-III breast cancer: Multicenter study","volume":"12","author":"Kitajima","year":"2021","journal-title":"Oncotarget"},{"key":"10.1053\/j.semnuclmed.2022.05.001_bib0045","first-page":"290","article-title":"Breast cancer-major changes in the American joint committee on cancer eighth edition cancer staging manual","volume":"67","author":"Giuliano","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"10.1053\/j.semnuclmed.2022.05.001_bib0046","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1245\/s10434-018-6486-6","article-title":"Eighth edition of the AJCC cancer staging manual: Breast cancer","volume":"25","author":"Giuliano","year":"2018","journal-title":"Ann Surg Oncol"},{"key":"10.1053\/j.semnuclmed.2022.05.001_bib0047","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s12282-008-0065-9","article-title":"Comparison of FDG-PET and MRI for evaluating the tumor extent of breast cancer and the impact of FDG-PET on the systemic staging and prognosis of patients who are candidates for breast-conserving therapy","volume":"16","author":"Uematsu","year":"2009","journal-title":"Breast Cancer"},{"key":"10.1053\/j.semnuclmed.2022.05.001_bib0048","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.2967\/jnumed.108.052050","article-title":"Breast cancer staging in a single session: Whole-body PET\/CT mammography","volume":"49","author":"Heusner","year":"2008","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.05.001_bib0049","doi-asserted-by":"crossref","DOI":"10.1016\/j.suronc.2021.101567","article-title":"PET\/CT in breast cancer staging is useful for evaluation of axillary lymph node and distant metastases","volume":"38","author":"Davidson","year":"2021","journal-title":"Surg Oncol"},{"key":"10.1053\/j.semnuclmed.2022.05.001_bib0050","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.clbc.2013.12.004","article-title":"Diagnostic performance of dedicated positron emission mammography using fluorine-18-fluorodeoxyglucose in women with suspicious breast lesions: a meta-analysis","volume":"14","author":"Caldarella","year":"2014","journal-title":"Clin Breast Cancer"},{"key":"10.1053\/j.semnuclmed.2022.05.001_bib0051","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.3389\/fonc.2020.01301","article-title":"Progress and future trends in PET\/CT and PET\/MRI molecular imaging approaches for breast cancer","volume":"10","author":"Ming","year":"2020","journal-title":"Front Oncol"},{"key":"10.1053\/j.semnuclmed.2022.05.001_bib0052","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejrad.2014.09.008","article-title":"Simultaneous whole-body (18)F-FDG-PET-MRI in primary staging of breast cancer: A pilot study","author":"Taneja","year":"2014","journal-title":"Eur J Radiol"},{"key":"10.1053\/j.semnuclmed.2022.05.001_bib0053","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1200\/JCO.2004.04.148","article-title":"Prospective multicenter study of axillary nodal staging by positron emission tomography in breast cancer: A report of the staging breast cancer with PET Study Group","volume":"22","author":"Wahl","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2022.05.001_bib0054","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1093\/annonc\/mdl425","article-title":"A comparative study on the value of FDG-PET and sentinel node biopsy to identify occult axillary metastases","volume":"18","author":"Veronesi","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1053\/j.semnuclmed.2022.05.001_bib0055","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1200\/JCO.2011.38.1103","article-title":"Prospective study of 2-[18F]fluorodeoxyglucose positron emission tomography in the assessment of regional nodal spread of disease in patients with breast cancer: An Ontario clinical oncology group study","volume":"30","author":"Pritchard","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2022.05.001_bib0056","doi-asserted-by":"crossref","first-page":"405","DOI":"10.2967\/jnumed.110.081711","article-title":"The sentinel node procedure in breast cancer: nuclear medicine as the starting point","volume":"52","author":"Hindi\u00e9","year":"2011","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.05.001_bib0057","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.ejso.2011.01.003","article-title":"Positron emission tomography (PET) for assessment of axillary lymph node status in early breast cancer: A systematic review and meta-analysis","volume":"37","author":"Cooper","year":"2011","journal-title":"Eur J Surg Oncol"},{"key":"10.1053\/j.semnuclmed.2022.05.001_bib0058","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.3390\/jcm10071543","article-title":"Pretherapeutic imaging for axillary staging in breast cancer: A systematic review and meta-analysis of ultrasound, MRI and FDG-PET","volume":"10","author":"Le Boulc'h","year":"2021","journal-title":"J Clin Med"},{"key":"10.1053\/j.semnuclmed.2022.05.001_bib0059","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/1471-2407-8-165","article-title":"Utility of 18F-fluoro-deoxyglucose emission tomography\/computed tomography fusion imaging (18F-FDG-PET\/CT) in combination with ultrasonography for axillary staging in primary breast cancer","volume":"8","author":"Ueda","year":"2008","journal-title":"BMC Cancer"},{"key":"10.1053\/j.semnuclmed.2022.05.001_bib0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta15040","article-title":"Positron emission tomography (PET) and magnetic resonance imaging (MRI) for the assessment of axillary lymph node metastases in early breast cancer: Systematic review and economic evaluation","volume":"15","author":"Cooper","year":"2011","journal-title":"Health Technol Assess"},{"key":"10.1053\/j.semnuclmed.2022.05.001_bib0061","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0260804","article-title":"Prospective comparison of CT and 18F-FDG-PET\/MRI in N and M staging of primary breast cancer patients: Initial results","volume":"16","author":"Bruckmann","year":"2021","journal-title":"PLoS One"},{"key":"10.1053\/j.semnuclmed.2022.05.001_bib0062","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1007\/s00259-021-05502-0","article-title":"Comparison of nodal staging between CT, MRI, and [18F]-FDG-PET\/MRI in patients with newly diagnosed breast cancer","volume":"49","author":"Morawitz","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2022.05.001_bib0063","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1007\/s00259-009-1145-6","article-title":"Diagnostic value of full-dose FDG-PET\/CT for axillary lymph node staging in breast cancer patients","volume":"36","author":"Heusner","year":"2009","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2022.05.001_bib0064","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1097\/MNM.0000000000001466","article-title":"The new perspective of PET\/CT for axillary nodal staging in early breast cancer patients according to ACOSOG Z0011 trial PET\/CT axillary staging according to Z0011","volume":"42","author":"Kong","year":"2021","journal-title":"Nucl Med Commun"},{"key":"10.1053\/j.semnuclmed.2022.05.001_bib0065","doi-asserted-by":"crossref","DOI":"10.1097\/RLU.0000000000003683","article-title":"The challenge of staging breast cancer with PET\/CT in the era of COVID vaccination","author":"Brown","year":"2021","journal-title":"Clin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.05.001_bib0066","first-page":"1729","article-title":"Impact of radical surgery on outcome in locally advanced breast cancer patients without metastasis at the time of diagnosis","volume":"35","author":"Nikpayam","year":"2015","journal-title":"Anticancer Res"},{"key":"10.1053\/j.semnuclmed.2022.05.001_bib0067","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.ijrobp.2018.07.2025","article-title":"FDG\/PET-CT-based lymph node atlas in breast cancer patients","volume":"103","author":"Borm","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1053\/j.semnuclmed.2022.05.001_bib0068","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.radonc.2019.08.021","article-title":"Irradiation of regional lymph node areas in breast cancer - Dose evaluation according to the Z0011, AMAROS, EORTC 10981-22023 and MA-20 field design","volume":"142","author":"Borm","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1053\/j.semnuclmed.2022.05.001_bib0069","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1148\/radiol.12110853","article-title":"Performance of FDG-PET\/CT in the clinical management of breast cancer","volume":"266","author":"Groheux","year":"2013","journal-title":"Radiology"},{"key":"10.1053\/j.semnuclmed.2022.05.001_bib0070","doi-asserted-by":"crossref","first-page":"3154","DOI":"10.1200\/JCO.2009.27.5743","article-title":"Integrated positron emission tomography\/computed tomography may render bone scintigraphy unnecessary to investigate suspected metastatic breast cancer","volume":"28","author":"Morris","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2022.05.001_bib0071","doi-asserted-by":"crossref","first-page":"3375","DOI":"10.1200\/JCO.1998.16.10.3375","article-title":"Detection of bone metastases in breast cancer by 18FDG-PET: Differing metabolic activity in osteoblastic and osteolytic lesions","volume":"16","author":"Cook","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2022.05.001_bib0072","doi-asserted-by":"crossref","DOI":"10.1053\/j.semnuclmed.2022.01.003","article-title":"A role of PET\/MR in breast cancer?","author":"Bruckmann","year":"2022","journal-title":"Semin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.05.001_bib0073","doi-asserted-by":"crossref","first-page":"8714","DOI":"10.1007\/s00330-021-07956-0","article-title":"Prospective comparison of the diagnostic accuracy of 18F-FDG-PET\/MRI, MRI, CT, and bone scintigraphy for the detection of bone metastases in the initial staging of primary breast cancer patients","volume":"31","author":"Bruckmann","year":"2021","journal-title":"Eur Radiol"},{"key":"10.1053\/j.semnuclmed.2022.05.001_bib0074","article-title":"FDG-PET\/CT in high-risk primary breast cancer-a prospective study of stage migration and clinical impact","author":"Vogsen","year":"2020","journal-title":"Breast Cancer Res Treat"},{"key":"10.1053\/j.semnuclmed.2022.05.001_bib0075","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1007\/s00259-015-3080-z","article-title":"Appearance of untreated bone metastases from breast cancer on FDG-PET\/CT: importance of histologic subtype","volume":"42","author":"Dashevsky","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2022.05.001_bib0076","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.2967\/jnumed.115.161455","article-title":"Comparison of 18F-FDG-PET\/CT for systemic staging of newly diagnosed invasive lobular carcinoma vs invasive ductal carcinoma","volume":"56","author":"Hogan","year":"2015","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.05.001_bib0077","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1007\/s00259-017-3709-1","article-title":"18F-FDG-PET\/CT for systemic staging of patients with newly diagnosed ER-positive and HER2-positive breast cancer","volume":"44","author":"Ulaner","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"10.1053\/j.semnuclmed.2022.05.001_bib0078","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/RLU.0000000000003502","article-title":"Impact of 18F-FDG-PET, PET\/CT, and PET\/MRI on staging and management as an initial staging modality in breast cancer: A systematic review and meta-analysis","volume":"46","author":"Han","year":"2021","journal-title":"Clin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.05.001_bib0079","doi-asserted-by":"crossref","first-page":"3173","DOI":"10.3390\/jcm10143173","article-title":"Relationship between prognostic stage in breast cancer and fluorine-18 fluorodeoxyglucose positron emission tomography\/computed tomography","volume":"10","author":"Mori","year":"2021","journal-title":"J Clin Med"},{"key":"10.1053\/j.semnuclmed.2022.05.001_bib0080","unstructured":"NCCN Clinical Practice Guidelines in Oncology. Breast cancer. Version 2. 2022. Available at: https:\/\/www.nccn.org\/professionals\/physician_gls\/f_guidelines.asp."},{"key":"10.1053\/j.semnuclmed.2022.05.001_bib0081","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2020.102943","article-title":"[18F]FDG-PET\/CT in the staging of inflammatory breast cancer: A systematic review","volume":"151","author":"van Uden","year":"2020","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1053\/j.semnuclmed.2022.05.001_bib0082","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1007\/s00259-016-3402-9","article-title":"18)F-FDG-PET\/CT for systemic staging of newly diagnosed triple-negative breast cancer","volume":"43","author":"Ulaner","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2022.05.001_bib0083","doi-asserted-by":"crossref","first-page":"252","DOI":"10.2967\/jnumed.116.178749","article-title":"Rate of distant metastases on 18F-FDG-PET\/CT at initial staging of breast cancer: comparison of women younger and older than 40 years","volume":"58","author":"Lebon","year":"2017","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.05.001_bib0084","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1245\/s10434-019-08194-x","article-title":"Response to letter to the editor: \u201c18FDG-PET\/CT imaging in breast cancer patients with clinical stage IIB or higher.\u201d","volume":"27","author":"Srour","year":"2020","journal-title":"Ann Surg Oncol"},{"key":"10.1053\/j.semnuclmed.2022.05.001_bib0085","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.6004\/jnccn.2020.7592","article-title":"Clinical utility of 18F-FDG-PET\/CT in staging localized breast cancer before initiating preoperative systemic therapy","volume":"18","author":"Ko","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1053\/j.semnuclmed.2022.05.001_bib0086","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.6004\/jnccn.2020.7598","article-title":"Use of 18F-FDG-PET\/CT as an initial staging procedure for stage II-III breast cancer: A multicenter value analysis","volume":"18","author":"Hyland","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1053\/j.semnuclmed.2022.05.001_bib0087","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1258\/ar.2011.110245","article-title":"FDG-PET\/CT in the diagnosis of recurrent breast cancer","volume":"53","author":"Murakami","year":"2012","journal-title":"Acta Radiol"},{"key":"10.1053\/j.semnuclmed.2022.05.001_bib0088","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s13550-021-00833-3","article-title":"Benefits and harms of implementing [18F]FDG-PET\/CT for diagnosing recurrent breast cancer: A prospective clinical study","volume":"11","author":"Vogsen","year":"2021","journal-title":"EJNMMI Res"},{"key":"10.1053\/j.semnuclmed.2022.05.001_bib0089","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s10549-004-3291-7","article-title":"A meta-analysis of FDG-PET for the evaluation of breast cancer recurrence and metastases","volume":"90","author":"Isasi","year":"2005","journal-title":"Breast Cancer Res Treat"},{"key":"10.1053\/j.semnuclmed.2022.05.001_bib0090","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1200\/JCO.2015.63.5185","article-title":"[18F]Fluorodeoxyglucose (FDG)-Positron Emission Tomography (PET)\/Computed Tomography (CT) in suspected recurrent breast cancer: a prospective comparative study of dual-time-point FDG-PET\/CT, Contrast-Enhanced CT, and bone scintigraphy","volume":"34","author":"Hildebrandt","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2022.05.001_bib0091","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1007\/s00432-009-0746-6","article-title":"FDG-PET and other imaging modalities for the evaluation of breast cancer recurrence and metastases: a meta-analysis","volume":"136","author":"Pan","year":"2010","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2022.05.001_bib0092","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta14500","article-title":"A systematic review of positron emission tomography (PET) and positron emission tomography\/computed tomography (PET\/CT) for the diagnosis of breast cancer recurrence","volume":"14","author":"Pennant","year":"2010","journal-title":"Health Technol Assess"},{"key":"10.1053\/j.semnuclmed.2022.05.001_bib0093","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.ejrad.2015.12.010","article-title":"Evaluation of 18F-FDG-PET\/MRI, 18F-FDG-PET\/CT, MRI, and CT in whole-body staging of recurrent breast cancer","volume":"85","author":"Sawicki","year":"2016","journal-title":"Eur J Radiol"},{"key":"10.1053\/j.semnuclmed.2022.05.001_bib0094","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1097\/MNM.0000000000000573","article-title":"Diagnostic efficacy of 18F-FDG-PET or PET\/CT in breast cancer with suspected recurrence: A systematic review and meta-analysis","volume":"37","author":"Xiao","year":"2016","journal-title":"Nucl Med Commun"},{"issue":"Suppl 1","key":"10.1053\/j.semnuclmed.2022.05.001_bib0095","article-title":"FDG-PET, PET\/CT, and breast cancer imaging","volume":"27","author":"Rosen","year":"2007","journal-title":"Radiographics"},{"key":"10.1053\/j.semnuclmed.2022.05.001_bib0096","doi-asserted-by":"crossref","first-page":"479","DOI":"10.2214\/ajr.183.2.1830479","article-title":"Impact of FDG-PET on defining the extent of disease and on the treatment of patients with recurrent or metastatic breast cancer","volume":"183","author":"Eubank","year":"2004","journal-title":"AJR Am J Roentgenol"},{"key":"10.1053\/j.semnuclmed.2022.05.001_bib0097","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1097\/RLU.0b013e31824850b0","article-title":"Tumor marker-guided PET in breast cancer patients-a recipe for a perfect wedding: a systematic literature review and meta-analysis","volume":"37","author":"Evangelista","year":"2012","journal-title":"Clin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.05.001_bib0098","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1159\/000507707","article-title":"How useful are tumor markers in detecting metastases with FDG-PET\/CT during breast cancer surveillance?","volume":"98","author":"Corso","year":"2020","journal-title":"Oncology"}],"container-title":["Seminars in Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001299822000514?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001299822000514?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T22:38:13Z","timestamp":1757543893000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0001299822000514"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":98,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S0001299822000514"],"URL":"https:\/\/doi.org\/10.1053\/j.semnuclmed.2022.05.001","relation":{},"ISSN":["0001-2998"],"issn-type":[{"value":"0001-2998","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"FDG-PET\/CT for Primary Staging and Detection of Recurrence of Breast Cancer","name":"articletitle","label":"Article Title"},{"value":"Seminars in Nuclear Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.semnuclmed.2022.05.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}